Company / Working Capital
Corcept Therapeutics Incorporated Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$319.4M
FY2025
5-year range
$218.9M / $426.8M
FY2021-FY2025
Trend
-3.5%
vs FY2024
Sector context
#134 of 213
Health Care
What the data says
At $319M, Corcept Therapeutics Incorporated's working capital ranks #134 of 213 in the Health Care sector. Working Capital has declined for 3 consecutive years, from $427M in FY2022 to $319M in FY2025.
Based on SEC 10-K filings.
$319M in FY2025 with a 5-year CAGR of -5.8%.
Declined from $354M to $319M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -9.2%
- 5-Year CAGR
- -5.8%
- 10-Year CAGR
- -
Sector benchmark
#134 of 213 in Health CareTop 63% of 213This company $319.4M Sector average $934.6M
▼
-65.8% below sector average
Key checks
Key Insights
- Corcept Therapeutics Incorporated's working capital has declined for 3 consecutive years.
- 5-year CAGR of -5.8%, indicating a declining trend.
- In FY2025, working capital decreased 3.5% year-over-year.
- Ranks #134 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.44 (safe zone, above 2.9 threshold)
- Strong profit margin: 20.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $319.4M | -3.5% |
| FY2024 | $330.8M | -6.6% |
| FY2023 | $354.1M | -17.0% |
| FY2022 | $426.8M | +94.9% |
| FY2021 | $218.9M | -49.2% |
| FY2020 | $431.0M | +60.5% |
| FY2019 | $268.5M | +33.4% |
| FY2018 | $201.2M | +112.7% |
| FY2017 | $94.6M | +146.9% |
| FY2016 | $38.3M | +36.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026